Document:

Exhibit 10.12

	
        New York office:

        24 West 40th Street, 8th Fl

        New York, NY, 10018

        Tel: +1-646-350-0702

        Fax: +1-646-843-9352
	
        London office:

        75 Wimpole Street

        London W1G 9RS

        Tel: +44 (0) 20 80040270

        Fax: +44 (0) 20 3318 3004

 

 

 

Private & Confidential

Addressee Only

Ray Prudo

76 Wimpole Street

London W1G 9RT

 

21 September 2015

 

Dear Ray

 

Chairmanship of Akari Therapeutics, Plc

 

I am writing to you in view of the forthcoming
completion of the share exchange agreement dated 10 July 2015 made between Celsus Therapeutics Plc (the “Company”)
and RPC Pharma Limited (“RPC”), pursuant to which the Company will purchase all capital stock of Volution Immuno
Pharmaceuticals SA (“Volution”) from RPC, Volution’s sole shareholder, in exchange for ordinary shares
of the Company, and the Company will be renamed Akari Therapeutics, Plc (“Completion”).

 

We are pleased to set out the basis on
which the Company’s Board of Directors (the “Board”) offers to appoint you as Chairman and a director
(“Director”) of the Company upon Completion, on and subject to the terms set out in this Letter.

 

Appointment and Status

 

Your appointment as Chairman and Director
of the Company will take effect from, and be conditional upon, Completion (at which time it is envisaged that the Company will
change its name to Akari Therapeutics, Plc). It is currently envisaged that Completion will occur on or around 16 September 2015
(and for the avoidance of doubt, if Completion does not take place by 31 December 2015, the terms of this Letter shall be null
and void and shall have no effect).

 

Your appointment will be subject to the
Company’s Articles of Association (the “Articles”) as amended from time to time, whether by the relationship
agreement dated 10 July 2015 made between the Company and RPC (the “Relationship Agreement”) or otherwise. Copies
of the Articles and Relationship Agreement are enclosed for your information.

 

We should also make it clear that these
terms and conditions constitute a contract for services, and not a contract of employment. This role will supersede any current
role you have with Volution and it is a condition of this offer that you resign from any current employment with Volution (conditional
upon Completion) in a form acceptable to the Company if so requested. By accepting this offer, you also confirm that you are not
subject to any restrictions that could prevent you from holding this office as Chairman and/or Director.

 

    	 	1	 

     

    

 

Duties and Responsibilities

 

In your role as Chairman, subject to changes
in prevailing corporate governance practice or future decisions by the Board, you will generally be expected to:

 

		·	chair the Company’s Board meetings,
and attend strategic meetings, general meetings and meetings of the Research & Development Committee (which includes setting
the agenda for such meetings); 

 

		·	attend meetings of other Board Committees
as appropriate; 

 

		·	set the Company’s strategic direction,
working with the Board;

 

		·	promote the highest standards of integrity,
probity and corporate governance throughout the Company and its divisions, particularly at Board level; 

 

		·	ensure, in conjunction with the Chief
Executive, that the Board receives accurate, timely and clear information; 

 

		·	contribute to effective communication
with shareholders; 

 

		·	facilitate the effective contribution
of the other non-executive directors and ensure constructive relations between executive and non-executive directors; and

 

		·	work closely with the Chief Executive.

 

You may request all relevant information
about the affairs of the Company and its subsidiaries that is reasonably necessary for you to effectively discharge your duties.

 

As a director, you will be required to
act at all times in the best interests of the Company. In accordance with the Companies Act 2006 and any other applicable statute
or stock exchange rule, you will also owe certain fiduciary duties to the Company, including (without limitation) duties to:

 

		·	act within the powers conferred on you
by the Company’s Articles and by law;

 

		·	promote the success of the Company;

 

		·	exercise independent judgement;

 

		·	exercise reasonable care, skill and diligence;

 

		·	not accept benefits from third parties;
and

 

		·	avoid conflicts of interest, and declare
any interests in proposed transactions or arrangements, with the Company. 

 

It is your responsibility
to familiarise yourself with these duties and responsibilities. If you need clarification on any of these points, please let the
Company’s General Counsel and/or Company Secretary know.

 

You should carry out these responsibilities
in accordance with any prevailing law and regulation, including any applicable stock exchange listing requirements and/or corporate
governance obligations. In particular, you will comply with the Company’s policies from time to time regarding the dealing
of securities and conflicts of interest. Accordingly, you may not engage in any transactions in the Company’s securities
without first notifying the Company’s General Counsel and/or Company Secretary and obtaining his/her prior written approval.

 

Term

 

You will initially hold office as a Class
C Director for a three-year term, further to Article 19.2.3. Thereafter, you will be required to seek re-appointment on such basis
as the Articles may set out from time to time. You should note that you have no right to be re-nominated by the Board.

 

    	 	2	 

     

    

 

Notwithstanding the other
terms of this Letter, your appointment as Chairman and Director may also be terminated by the Company with immediate effect (without
being required to serve notice or make any payment in lieu of notice or other payment) should any of the events set out in Articles
25.1.2, 25.1.3, 25.1.4, 25.1.5 or 25.1.6 occur or if at any time you cease to be a Director.

 

On termination of your appointment (howsoever
arising), you will not be entitled to any compensation for loss of office, and you will only be entitled to such fees as may have
accrued to the date of termination (together with reimbursement in the normal way of expenses properly incurred before that date).
You will also resign from your office as director of the Company (and any offices you may hold in any of the Company’s group
companies) as the Board may direct.

 

Fees and Expenses

 

Your fee will be US$200,000 per annum.
This shall accrue, and be payable, in equal monthly instalments, subject to deductions of income tax and National Insurance as
required by law.

 

The Company will reimburse you for any
reasonable expenses properly incurred in attending the Board and Committee meetings or otherwise on Company business, subject to
your provision of receipts or such other documentation as the Company may reasonably require. The Company may also grant you other
benefits commensurate with your position from time to time.

 

Notwithstanding anything contained herein
or in any incentive compensation plan, program or arrangement sponsored by the Company, if any incentive or performance-based compensation
is awarded to you, it shall be subject to reduction or repayment by reason of a correction or restatement of the Company’s
financial information if and to the extent such reduction or repayment is required by any applicable law or stock exchange rule.

 

Attendance

 

By accepting the appointment, you agree
to commit sufficient time for the proper performance of your duties to the Company. This will include attendance at the meetings
mentioned above, the AGM and other shareholder meetings, and other ad hoc Board and Committee meetings (as required), along
with travelling time and generally sufficient time for you to prepare for meetings and to regularly update and refresh your skills
and knowledge with regard to your role.

 

The nature of the role makes it impossible
to be specific about the maximum time commitment that will be required by you, but it should average no more than 10 days per month
at most. You may be required to devote additional time to the Company in respect of preparation time and any ad hoc matters
that may arise, particularly when the Company is undergoing periods of increased activity. At certain times it may be necessary
to convene additional Board, committee, shareholder or other meetings.

 

Outside Interests

 

During the term of your appointment, you
should therefore obtain prior written authorisation from the Board before accepting any other directorships or business commitments
that could affect the time you are able to devote to your role with the Company, impinge on the proper performance of your responsibilities,
or give rise to a conflict of interest with the Company.

 

You have already disclosed the following
commitments/positions to the Board:

		·	Chairman, CIS Healthcare Ltd.

		·	Chairman, The Doctors Laboratory Ltd.

		·	Chairman, Varleigh Dx (UK) Ltd.

 

    	 	3	 

     

    

 

If you become aware of any actual or potential
conflicts of interest which affect or relate to the Company, whether in relation to these commitments/positions or otherwise, you
should immediately inform the Company’s General Counsel and/or Company Secretary.

 

Confidentiality 

 

In your capacity as Chairman and Director,
you will become aware of confidential information about the business, affairs, plans and prospects of the Company and its subsidiaries.
In common with all other directors, you owe a duty of confidentiality to the Company and its subsidiaries in respect of such information
and, notwithstanding any other positions you may hold (whether as a director, adviser, employee, partner, investor, person connected
with an investor or otherwise), no such information should be used, divulged or communicated to any person, firm or organisation
other than in the proper performance of your duties or with the consent of the Board or as required by a court of competent jurisdiction.
This duty of confidentiality will continue to apply after you have ceased to be a director.

 

I would also draw your attention to the
various legal and regulatory requirements that apply to the disclosure of inside information and insider dealing, in particular
Regulation FD and Rule 10b-5 under the Securities Exchange Act of 1934, as amended. You should avoid making any statements or carrying
out any actions that might risk a breach of these requirements.

 

Liability

 

You will have the benefit of the indemnity
contained within the Articles for certain liabilities you may incur in the performance of your duties as a director of the Company.
The Company also maintains a directors’ and officers’ liability insurance policy in this regard.

 

You may take independent professional advice
at the Company’s reasonable expense where necessary for the proper performance of your duties. In such cases you are encouraged
to discuss the issue with one or more of your non-executive colleagues or the Company’s General Counsel and/or Company Secretary
in advance, and should obtain pre-approval of any such costs.

 

Administrative Matters

 

In order to formalise your appointment,
we will need certain information from you, so that your appointment can be notified to the NASDAQ Stock Market and Companies House
in the UK. Accordingly, I enclose two copies of this Letter and various forms for you to complete and return to the Company if
you wish to accept the appointment.

 

By signing this Letter, you also consent
to the Company holding and processing information about you for legal, personnel, administrative and management purposes, including
the processing of sensitive personal data (as defined in the Data Protection Act 1998). You consent to the Company making such
information available to any of its group companies, third parties who provide products and services to the Company (such as advisers
and payroll administrators), regulatory authorities and any other organisations which may have a legitimate need to receive this
information. You also consent to the transfer of such information outside the European Economic Area as necessary for the Company’s
business interests and administration.

 

Governing Law

 

This Letter is governed by, and shall be
construed in accordance with, the laws of England, and the parties agree to submit to the jurisdiction of the courts of England.
It contains the entire agreement and understanding between the parties in relation to the matters set out herein, and replaces
all previous negotiations, agreements, arrangements or understandings (whether implied or expressed, orally or in writing) in this
regard, which are hereby treated as terminated by mutual consent.

 

    	 	4	 

     

    

 

I trust the above is all in order, but
please don’t hesitate to contact me if you have any questions.

 

Yours sincerely

 

 

 

/s/ Gur Roshwalb

...............................................................

For and on behalf of Akari Therapeutics,
Plc

 

 

 

 

I agree to the terms and conditions of
my appointment as Chairman and director of Akari Therapeutics, Plc with effect from Completion on the basis set out above.

 

 

	/s/ Ray
Prudo	 	21/9/2015
	Agreed by Ray Prudo	 	Date

 

    	 	5Exhibit 10.13

 

	
        New York office:

        24 West 40th Street, 8th Fl

        New York, NY, 10018

        Tel: +1-646-350-0702

        Fax: +1-646-843-9352
	
        London office:

        75 Wimpole Street

        London W1G 9RS

        Tel: +44 (0) 20 80040270

        Fax: +44 (0) 20 3318 3004

 

 

 

Private & Confidential 

Addressee Only 

Ray Prudo

76 Wimpole Street

London W1G 9RT

21 September 2015

 

Dear Ray

 

 

 

Side letter: your engagement with Celsus Therapeutics Limited
(the “Company”)

 

As recently discussed, I am writing to
confirm the value of your services to the Company as Chairman and director, and our belief that it would be in the best interests
of the Company and its ultimate shareholders to enter into the arrangements set out in this Letter, on and subject to its terms.

 

Accordingly, I am pleased to confirm that
you will be eligible to be considered for an additional cash payment (a “Fee Uplift”) in each calendar year
in respect of which the Board (or appropriate sub-committee) reasonably concludes, in its absolute discretion, that your strategic
leadership in the role of Chairman has generated exceptional value for the Company and its ultimate shareholders.

 

In assessing the amount of any such Fee
Uplift, the Board (or appropriate sub-committee) will consider relevant factors, potentially including (without limitation) Company
performance and relevant legal obligations, stock exchange rules, and corporate governance requirements. The maximum amount of
any Fee Uplift will be as set by the appropriate sub-committee in its absolute discretion for the relevant calendar year. Any Fee
Uplift will be paid to you as a US$ cash payment, less all applicable withholdings required by law.

 

Payment of any Fee Uplift is conditional
upon your ongoing compliance with the terms of your Appointment, and your not having ceased to be Chairman and/or a director of
the Company by reason of your resignation or further to Article 25.1.2, 25.1.3, 25.1.4, 25.1.5 and/or 25.1.6 of the Company’s
Articles of Association (as amended from time to time) as at the date on which the relevant Fee Uplift is due to be paid. In addition,
any payment made to you further to this Letter shall be subject to reduction or repayment by reason of a correction or restatement
of the Company’s financial information, if and to the extent such reduction or repayment is required by any applicable law
or stock exchange rule.

 

This Letter supplements the terms of your
letter of appointment with the Company dated on or around the date of this Letter (your “Appointment”), and
defined terms not otherwise defined in this Letter will have the meaning set out in the Appointment. Like your Appointment, this
Letter will take effect from, and be conditional upon, Completion, and similarly if Completion does not take place by 31 December
2015, its terms will be null and void and shall have no effect. The terms of your Appointment will continue unchanged save as set
out in this Letter.

 

    	 	1	 

     

    

 

This Letter is governed by, and shall be
construed in accordance with, the laws of England, and the parties agree to submit to the jurisdiction of the courts of England.
It contains the entire agreement and understanding between the parties in relation to the matters set out herein, and replaces
all previous negotiations, agreements, arrangements or understandings (whether implied or expressed, orally or in writing) in this
regard, which are hereby treated as terminated by mutual consent.

 

I trust the above is all in order, but
please don’t hesitate to contact me if you have any questions.

 

 

Yours sincerely

 

 

/s/ Gur Roshwalb

...........................................................

 

For and on behalf of Akari Therapeutics, Plc

 

    	 	2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}]]